PREX2 and breast cancer: Moreover, the highest mutational frequencies of TP53 (84.21% vs. 61.62% vs. 43.29%, p = 3.778 E‐06), MYC (13.16% vs. 3.03% vs. 3.66%, p = 0.047), FAT4 (13.16% vs. 8.08% vs. 1.22%, p = 0.0009), PBRM1 (7.89% vs. 0.0% vs. 0.61%, p = 0.007), and PREX2 (7.89% vs. 1.01% vs. 1.22%, p = 0.035) were analyzed to be dramatically different in BC PD‐L1‐H cohort compared to that in PD‐L1‐L and PD‐L1‐negative cohort (Figure 4F).